Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 659-666 , December 2008

What is the role of arsenic in newly diagnosed APL?

  • Martin S. Tallman, MD (Professor of Medicine, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL)

      Affiliations

    • Corresponding Author InformationTel.: +312 695 6180; Fax: +312 695 6189.

References 

  1. Rodeghiero F, Castaman G. The pathophysiology and treatment of hemorrhagic syndrome of acute promyelocytic leukemia. Leukemia. 1994;8(Suppl. 2):S20–S26
  2. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110:59–66
  3. Avvisati G, Petti MC, Lo-Coco F, et al. AIDA: the Italian way of treating acute promyelocytic leukemia (APL), final act. Blood. 2003;102:142a;[abstract 487]
  4. Ades L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood. 2008;111:1078–1084
  5. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 2001;19:3852–3860
  6. Glienke W, Chow KU, Bauer N, et al. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leukemia & Lymphoma. 2006;47:1629–1638
  7. Mathieu J, Besancon F. Arsenic trioxide represses NF-kappaB activation and increases apoptosis in ATRA-treated APL cells. Annals of the New York Academy of Sciences. 2006;1090:203–208
  8. Ninomiya M, Kajiguchi T, Yamamoto K, et al. Increased oxidative DNA products in patients with acute promyelocytic leukemia during arsenic therapy. Haematologica. 2006;91:1571–1572
  9. Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. Journal of Clinical Oncology. 2007;25:1s;[abstract 2]
  10. Liu YF, Zhu YM, Shi ZZ, et al. Long-term follow-up confirms the benefit of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) as front line therapy for newly diagnosed acute promyelocytic leukemia (APL). Blood. 2006;108:170a;[abstract 565]
  11. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–2632
  12. Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. Journal of Clinical Oncology. 2006;24:5703–5710
  13. Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004;103:1237–1243
  14. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2004;101:5328–5335
  15. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469–3473
  16. Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. Journal of Biological Regulators and Homeostatic Agents. 1999;13:195–200
  17. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Annals of Oncology. 2006;17:131–134
  18. Ghaffari SH, Shayan-Asl N, Jamialahmadi A, et al. Telomerase activity and telomere length in APL: may be proliferative and prognosti markers. Blood. 2007;110:126b;[abstract 4236]
  19. Mathews V, Thomas M, Srivastava VM, et al. Impact of FLT3 mutations and secondary cytogenetic changes on the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with a single agent arsenic trioxide regimen. Haematologica. 2007;92:994–995
  20. Alimoghaddam K, Ghavamzadeh A, Rostami S, et al. Risk factors for early mortality, relapse and overall survival in new cases of APL treated by arsenic trioxide. Journal of Clinical Oncology. 2007;25:374s;[abstract 7069]
  21. Stock W, Najib K, Moser BK, et al. High incidence of FLT3 mutations in adults with Acute Promyelocytic Leukemia (APL): correlation with diagnostic features and treatment outcome (CALGB 9710). Journal of Clinical Oncology. 2008;26:372s;[abstract 7002]
  22. Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005;106:3768–3776
  23. Sainty D, Liso V, Cantu-Rajnoldi A, et al. A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. Group Francais de Cytogenetique Hematologique, UK Cancer Cytogenetics Group and BIOMED 1 European Coomunity-Concerted Acion "Molecular Cytogenetic Diagnosis in Haematological Malignancies. Blood. 2000;96:1287–1296
  24. Ito S, Ishida Y, Oyake T, et al. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leukemia & Lymphoma. 2004;45:1783–1789
  25. Douer D, Santillana S, Ramezani L, et al. Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. British Journal of Haematology. 2003;122:563–570
  26. Wang ZY, Chen Z, Huang W, et al. Problems existing in differentiation therapy of acute promyelocytic leukemia (APL) with all-trans retinoic acid (ATRA). Blood Cells. 1993;19:633–641
  27. Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997;90:967–973
  28. Kini AR, Peterson LA, Tallman MS, et al. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–3924
  29. Banavali SD, Goyal L, Nair R, et al. A novel, efficacious therapeutic approach to patients with acute promyelocytic leukemia (APL) using differentiating agent and metronomic chemotherapy (CT). Blood. 2005;106:264a;[abstract 900]
  30. Kini AR, Roychowdhury S, Dziuma A, et al. Vascular endothelial growth factor (VEGF) is a critical autocrine survival factor in acute promyelocytic leukemia (APL). Blood. 2005;106:772a;[abstract 2751]
  31. Sassano A, Katsoulidis E, Antico G, et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Research. 2007;67:4524–4532

PII: S1521-6926(08)00088-1

doi: 10.1016/j.beha.2008.09.002

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 659-666 , December 2008

Article Tools